BioCentury
ARTICLE | Strategy

Takeda’s modality operandi

How Takeda is using external innovation to access new modalities

June 24, 2017 12:45 AM UTC

Takeda Pharmaceutical Co. Ltd. is moving beyond its traditional small molecule approach into new modalities with the goal of delivering therapeutics that provide a step change for patients. To get there, Takeda is using a wide range of collaborations that leverage the company’s expertise while also tapping its partners’ skill sets.

BioCentury sat down with Takeda Chief Medical and Scientific Officer Andrew Plump at BIO’s annual meeting in San Diego to discuss his vision for growing Takeda’s pipeline...